Three years after it was formed as a spinout of Japanese drugmaker Takeda, Phathom Pharmaceuticals has racked up its first FDA approvals, and claimed a sizeable $260 million in new financing to ...

On Wednesday, Phathom Pharmaceuticals Inc (PHAT) stock saw a modest uptick, ending the day at $16.47 which represents a slight increase of $0.81 or 5.17% from the prior close of $15.66. The stock ...

Phathom Pharmaceuticals has received two approvals within a three-day span from the US Food and Drug Administration (FDA) for the heartburn drug Voquezna (vonoprazan). The first approval was ...

Phathom Pharmaceuticals developed Voquezna, a first-in-class PCAB, licensed from Takeda, for acid-related disorders. Voquezna's FDA approval for erosive esophagitis is based on superior efficacy ...

On Friday, Phathom Pharmaceuticals Inc (PHAT) stock saw a decline, ending the day at $15.09 which represents a decrease of $-0.62 or -3.95% from the prior close of $15.71. The stock opened at $15.63 ...

Phathom Pharmaceuticals (NASDAQ:PHAT) just reported results for the first quarter of 2024. Phathom Pharmaceuticals reported earnings per share of -$1.42. This was below the analyst estimate for ...

Avi Kapoor "Top Pick for 2024": Analyst Bullish On Phathom Pharmaceuticals On Voquezna Launch In Erosive GERD, Projecting $55.6M In Sales ...

The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Dexcom (DXCM – Research Report) and ...

Short interest in Phathom Pharmaceuticals Inc (NASDAQ:PHAT) increased during the last reporting period, rising from 14.25M to 15.34M. This put 40.09% of the company's publicly available shares short.

Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. The company ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...